ReviewEndocrine, metabolic & immune disorders drug targets2026
Type 2 Diabetes Mellitus in Saudi Arabia: Prevalence, Risk Factors, and Management Strategies: A Review.
Review in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Wheat Bioactive Compounds and Human Health: A Review of Nutraceutical Potential, Molecular Mechanisms and AI-Assisted Functional Food Innovation.International journal of molecular sciences · 2026Review
- Association ofPakistan journal of medical sciences · 2026Article
- Survival and predictors of mortality among adults with type 2 diabetes at a teaching hospital in Ghana: a retrospective cohort study.BMC public health · 2026Article
- Interplay of childhood metabolic dysfunction-associated steatotic liver disease and obesity in the development of youth-onset type 2 diabetes.World journal of clinical pediatrics · 2026Article
- Comparison of the triglyceride/high-density lipoprotein ratio, lipid profile, and glycated hemoglobin and their association with coronary artery disease in the older adult Saudi population: a case-control study.Frontiers in cardiovascular medicine · 2026Article
- Association of NLRP3 Inflammasome rs10754558 Polymorphism with Type 2 Diabetes Mellitus and Its Complications: Clinical and Bioinformatics Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Factors Associated with Patient Treatment Satisfaction in Diabetes Mellitus Care Using the DTSQs: A Nationwide Cross-Sectional Study in Saudi Arabia.Patient preference and adherence · 2026Article
- Medication Adherence to Semaglutide versus Empagliflozin in Adults with Type 2 Diabetes: A Retrospective Observational Study in Saudi Arabia.Patient preference and adherence · 2025Article
- Pterostilbene Attenuates High Fat Diet-induced Obesity and Hepatic Dysfunction in Rats: A Functional Evaluation Based on Taiwan's Health Food Assessment Criteria.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus (DM) is a major health problem and a leading cause of death in the Kingdom of Saudi Arabia (KSA). The World Health Organization (WHO) ranks KSA as the seventh country with the highest diabetes prevalence in the world. The healthcare and treatment costs for diabetes have risen by more than 500% in the last two decades. Obesity is the main risk factor for type 2 diabetes mellitus (T2DM), which involves insulin resistance and β-cell dysfunction. Genetic and environmental factors also influence the development of T2DM. There are various options for controlling blood glucose in T2DM patients, including a new class of oral drugs called sodium-glucose transport protein 2 inhibitors (SGLT2i). These drugs reduce glucose reabsorption and increase glucose excretion in the kidney. They can be used at any stage of diabetes and have benefits such as lowering blood pressure, A1C levels, and body weight. Dapagliflozin is one of the SGLT2 inhibitors that T2DM patients well tolerate. This review examines the impact of T2DM in KSA, its risk factors and complications, and the role of Dapagliflozin in its management. It also provides expert opinions on the current situation of T2DM in KSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.